Objective: Urinary incontinence is defined as urinary incontinence that is a social or hygienic problem and can be objectively demonstrated. It is aimed to compare tolterodine, trospium chloride and solifenacin treatments, and its side effects on patients who have complaints of pure urinary and mixed incontinence.
Material and Method: Totally 98 patients, who applied to Ankara Etlik Zubeyde Hanım Gynecology Training and Research Hospital, Urogynecology Outpatient Clinic between November 2009 and October 2010 with compliants of urinary incontinence and met the criteria to participate in the research, have been included in this study.
Results: A significant improvement in each three of the drug group at third and six months was determined. Solifenacin is generally more effective than the other two treatments. When total values of UDI-6 (Urinary Distress Inventory) survey is analysed, it is seen that each of three antimuscarinic drug group ensured improvement on symptoms at the end of the third month as not to be different from the improvement at the six month. Each three antimuscarinic drug group has a significant therapeutic effect on the IIQ-7 (Incontinence Impact Questionnaire) survey which questions the life quality. Whereas complaints of constipation was seen more at patients that use tolterodine and trospium chloride, there was not a significant difference despite a slight increase in the solifenacin group (p>0.05). It is determined that solifenacin caused desert mouth less than the other two drug groups
Conclusion: Tolterodine, trospium chloride and solifenacin as anticholinergic drugs meaningfully reduced the activity of bladder and increased the quality of life. Drug therapy provided an effective and efficient improvement on incontinence.

References